Fiche société
NeurAxon Inc.
Traitements, essais et publications liés.
Traitements3programmes
Essais1liés
Publications5liées
SourceDBlocale
Traitements
3| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| NXN-188NXN-188 Dihydrochloride is being developed as an immediate release oral product for the treatment of acute migraine. This study is being conducted to evaluate NXN-188 in subjects with a migraine history of aura. | Migraine | Phase 2 | À vérifier | United States | À vérifier |
| sumatriptan succinateNXN-188 Dihydrochloride is being developed as an immediate release oral product for the treatment of acute migraine. This study is being conducted to evaluate NXN-188 in subjects with a migraine history of aura. | Migraine | Phase 2 | À vérifier | United States | À vérifier |
| NXN-188NXN-188 Dihydrochloride is being developed as an immediate release oral product for the treatment of acute migraine. This study is being conducted to evaluate NXN-188 in subjects with a migraine history of aura. | Migraine | Phase 2 | À vérifier | United States | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| NXN-188 | Migraine | Phase 2 | NCT00920686 | Study of NXN 188 for the Treatment of Migraine With Aura | COMPLETED |
Publications
5| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| NXN-188 | NXN-188, a selective nNOS inhibitor and a 5-HT1B/1D receptor agonist, inhibits CGRP release in preclinical migraine models. | Cephalalgia : an international journal of headache | ||
| sumatriptan succinate | Spatial metabolomics combined with MALDI-MSI unveils gut-brain axis mechanisms of angelica dahurica radix in migraine rats. | Phytomedicine : international journal of phytotherapy and phytopharmacology | ||
| sumatriptan succinate | Cellulose and Its Derivatives in Drug Delivery: Recent Advances and Applications. | Pharmaceutics | ||
| NXN-188 | Drugs targeting nitric oxide synthase for migraine treatment. | Expert opinion on investigational drugs | ||
| NXN-188 | The nitric oxide synthase inhibitor and serotonin-receptor agonist NXN-188 during the aura phase of migraine with aura: A randomized, double-blind, placebo-controlled cross-over study. | Scandinavian journal of pain |